The phase 1 dose-escalation trial in FRα positive solid tumors has shown promising data with 75% disease control rate (DCR) for the entire population, including 1 CR and 2 PR among the 9 patients with ovarian cancer included in the trial [43]. This evidence concerns the gene FOLR1 and ovarian carcinoma.